Nicotinamide riboside - ChromaDex

Drug Profile

Nicotinamide riboside - ChromaDex

Alternative Names: NIAGEN; Nicotinamide-beta-riboside; Nicotinamide-ribonucleoside; Nicotinamide-ribose; SRT-647

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer ChromaDex; Ecole Polytechnique Federale de Lausanne.; National Institutes of Health (USA); University of Cambridge; University of Iowa; Washington University
  • Class Amides; Analgesics; Nicotinic-acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Heart failure; Mitochondrial myopathies
  • Preclinical Alzheimer's disease; Ataxia telangiectasia; Cockayne syndrome; Pain

Most Recent Events

  • 20 Feb 2018 Clinical trials in Heart failure in USA (PO), prior to February 2018
  • 20 Feb 2018 Clinical trials in Mitochondrial myopathies in United Kingdom (unspecified route), prior to February 2018
  • 08 Feb 2018 Updated pharmacodynamics data from a preclinical study in Alzheimer's disease released by ChromaDex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top